|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|
37275957
|
Zaninetti C, Leinoe E, Lozano ML, Rossing M, Bastida JM, Zetterberg E, Rivera J, Greinacher A. Validation of immunofluorescence analysis of blood smears in patients with inherited platelet disorders. J Thromb Haemost. 2023 Apr;21(4):1010-1019. doi: 10.1016/j.jtha.2022.12.031. Epub 2023 Jan 10. PubMed PMID: 36732160.
AÑO: 2023; IF: 5.5
|
|
Lova A, Pagan J, de la Morena G, Vazquez DJ, Cerezo-Manchado JJ, Bravo-Perez C, Minano A, Tomas A, Vicente V, Lozano ML, Corral J, de la Morena-Barrio ME. Congenital factor XI deficiency and risk of heart failure in humans. J Thromb Haemost. 2023 Sep;21(9):2626-2629. doi: 10.1016/j.jtha.2023.06.013. Epub 2023 Jun 17. No abstract available. PubMed PMID: 37336435.
AÑO: 2023; IF: 5.5
|
|
Zapata-Martinez L, Aguila S, de Los Reyes-Garcia AM, Carrillo-Tornel S, Lozano ML, Gonzalez-Conejero R, Martinez C. Inflammatory microRNAs in cardiovascular pathology: another brick in the wall. Front Immunol. 2023 May 18;14:1196104. doi: 10.3389/fimmu.2023.1196104. eCollection 2023. PubMed PMID: 37275892; PubMed Central PMCID: PMC10233054.
AÑO: 2023; IF: 5.7
|
|
Zaragoza-Huesca D, Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Pena-Garcia J, Espin S, Ricote G, Nieto A, Garcia-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Perez-Sanchez H, Martinez-Martinez I. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. PubMed PMID: 37918256.
AÑO: 2023; IF: 6.9
|